source
- Moderna and Merck vaccine plus Keytruda cuts melanoma relapse risk by 42% in late-stage trialA late-stage adjuvant study of Moderna’s experimental melanoma vaccine, intismeran autogene, combined with Merck’s Keytruda showed a 42% reduction in the risk of relapse or death compared with Keyt…